Abstract
Background
The US Food and Drug Administration has approved orally administered 100-mg and 200-mg doses of lasmiditan for the acute treatment of migraine, with or without aura. Having a unique mechanism of action, lasmiditan is the first and only Food and Drug Administration-approved serotonin 5-HT1F receptor agonist.
Objective
The objective of this study was to systematically evaluate the efficacy and safety of lasmiditan for the acute treatment of migraine in adult patients.
Methods
We systematically searched PUBMED, EMBASE, and Cochrane Library databases. Any relevant articles published before 3 March, 2020 were collected. Inclusion criteria were: (1) randomized clinical trials; (2) enrolled adult participants diagnosed with migraine; (3) compared lasmiditan at 100 mg or 200 mg with placebo; (4) enrolled more than 100 participants; and (5) provided any available data for predefined primary or secondary outcomes.
Results
Three high-quality, multi-centered randomized clinical trials with 4506 patients in total were included. We found that the use of lasmiditan was related to a significantly increased rate of pain freedom at 2 h post-dose with 31.60% patients achieving freedom of pain in the lasmiditan group compared with 17.55% patients in the placebo group (relative risk [RR] 1.80 [95% confidence interval (CI) 1.34–2.42]), with no significant heterogeneity. In addition, lasmiditan is reported to significantly increase the rate of absence of the most bothersome symptoms at 2 h compared with the placebo group with no significant heterogeneity (lasmiditan, 42.82%; placebo, 30.38%; RR 1.44 [95% CI 1.03–2.01], I2 = 0%). With regard to the safety endpoints, compared with the placebo group, participants in the lasmiditan group had a higher rate of fatigue, paresthesia, and somnolence (fatigue: lasmiditan, 1.94%; placebo, 0.24%; RR 7.96 [95% CI 0.4–158.86]; paresthesia: lasmiditan, 6.91%; placebo, 1.56%; RR 4.46 [95% CI 1.54–12.93], somnolence: lasmiditan, 5.9%; placebo, 2.15%; RR 2.76 [95% CI, 1.49–5.11]) with low heterogeneity. A subgroup analysis demonstrated that without safety differences, participants who received the 200-mg dose had a higher percentage of freedom of pain at 2 h and sustained pain relief at 2–24 h compared with the 100-mg dose (freedom of pain at 2 h: lasmiditan, 34.53%; placebo, 28.67%; RR 1.2 [95% CI 1.04–1.38]; lasmiditan, 20.62%; placebo, 16.33%; RR 1.26 [95% CI 1.19–1.34]), with low heterogeneity for both outcomes (I2 = 0%).
Conclusions
In this meta-analysis, the use of lasmiditan as an acute treatment for episodic migraine in adults led to a greater percentage of freedom of pain and the absence of the most bothersome symptoms at 2 h post-dose. Lasmiditan 200 mg had superior efficacy to 100-mg dose without a significantly increased risk for adverse events.
Similar content being viewed by others
References
Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007;13(1):39–44.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
Raggi A, Covelli V, Schiavolin S, Giovannetti AM, Cerniauskaite M, Quintas R, et al. Psychosocial difficulties in patients with episodic migraine: a cross-sectional study. Neurol Sci. 2016;37(12):1979–86.
Koehler PJ, Tfelt-Hansen PC. History of methysergide in migraine. Cephalalgia. 2008;28(11):1126–35.
Long K, Long R. Sumatriptan for the treatment of acute migraine headache. Nurse Pract Forum. 1993;4(3):124–5.
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.
Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan: a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170–8.
Raffaelli B, Israel H, Neeb L, Reuter U. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother. 2017;18(13):1409–15.
Lamb YN. Lasmiditan: first approval. Drugs. 2019;79(18):1989–96.
Massiou H, Tzourio C, el Amrani M, Bousser MG. Verbal scales in the acute treatment of migraine: semantic categories and clinical relevance. Cephalalgia. 1997;17(1):37–9 (discussion 2).
Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
IntHout J, Ioannidis JP, Borm GF. The Hartung–Knapp–Sidik–Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian–Laird method. BMC Med Res Methodol. 2014;14:25.
R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/.
Farkkila M, Diener HC, Geraud G, Lainez M, Schoenen J, Harner N, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405–13.
Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222–32.
Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894–904.
Doty EG, Krege JH, Jin L, Raskin J, Halker Singh RB, Kalidas K. Sustained responses to lasmiditan: results from post-hoc analyses of two phase 3 randomized clinical trials for acute treatment of migraine. Cephalalgia. 2019;39(12):1569–76.
Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, et al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies. Headache. 2019;59(10):1788–801.
Loo LS, Plato BM, Turner IM, Case MG, Raskin J, Dowsett SA, et al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol. 2019;19(1):191.
Loo LS, Ailani J, Schim J, Baygani S, Hundemer HP, Port M, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20(1):84.
Tsai M, Case M, Ardayfio P, Hochstetler H, Wilbraham D. Effects of lasmiditan on cardiovascular parameters and pharmacokinetics in healthy subjects receiving oral doses of propranolol. Clin Pharmacol Drug Dev. 2020;5:629–38.
Tepper SJ, Krege JH, Lombard L, Asafu-Adjei JK, Dowsett SA, Raskin J, et al. Characterization of dizziness after lasmiditan usage: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials. Headache. 2019;59(7):1052–62.
Wilbraham D, Berg PH, Tsai M, Liffick E, Loo LS, Doty EG, et al. Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study. J Clin Pharmacol. 2020;60(4):495–504.
Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl. 4):221–35.
Xu H, Han W, Wang J, Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016;17(1):113.
Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633–58.
Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC. Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2017;57(10):1507–21.
Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–25.
Rubio-Beltran E, Labastida-Ramirez A, Haanes KA, van den Bogaerdt A, Bogers A, Zanelli E, et al. Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol. 2019;176(24):4681–95.
Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12(6):593–601.
Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43(4):376–88.
Lipton RB, Lombard L, Ruff DD, Krege JH, Loo LS, Buchanan A, et al. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. J Headache Pain. 2020;21(1):20.
Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, et al. Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019;39(11):1343–57.
Knievel K, Buchanan AS, Lombard L, Baygani S, Raskin J, Krege JH, et al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia. 2020;40(1):19–27.
Gao B, Yang Y, Wang Z, Sun Y, Chen Z, Zhu Y, et al. Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol. 2019;10:1577.
Yang Y, Chen M, Sun Y, Gao B, Chen Z, Wang Z. Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials. CNS Drugs. 2020;34(5):463–71.
Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, et al. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019;79(4):417–31.
Urits I, Clark G, An D, Wesp B, Zhou R, Amgalan A, et al. An evidence-based review of fremanezumab for the treatment of migraine. Pain Ther. 2020;9(1):195–215.
Author information
Authors and Affiliations
Contributions
YY was the main contributor to the design, statistical analysis, and writing of the first manuscript. YS was responsible for revising the manuscript, checking the collected data, and validating the included studies. Data collection, plotting, and editing analysis tables and graphs were allocated to other authors. ZC constructed the study and was in charge of overall direction and planning.
Corresponding author
Ethics declarations
Funding
This work was supported by the Suzhou Health Talents Training Project (GSWS2019002).
Conflict of interest
Yanbo Yang, Yue Sun, Bixi Gao, Zilan Wang, Zhouqing Chen, and Zhong Wang have no conflicts of interest that are directly relevant to the content of this article.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and material
Not applicable.
Code availability
Not applicable.
Electronic supplementary material
Below is the link to the electronic supplementary material.
40263_2020_753_MOESM3_ESM.docx
Supplement 3 Forest plots of all efficacy and safety endpoints, lasmiditan vs placebo and lasmiditan 200 mg vs lasmiditan 100 mg. CI confidence interval, RR relative risk (DOCX 1711 kb)
Rights and permissions
About this article
Cite this article
Yang, Y., Sun, Y., Gao, B. et al. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. CNS Drugs 34, 1015–1024 (2020). https://doi.org/10.1007/s40263-020-00753-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-020-00753-1